ReviewPsychological medicine2023
Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials.
Review in Psychological medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.Psychopharmacology · 2025Trial
- Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.Brain and behavior · 2026Article
- Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.Journal of psychopharmacology (Oxford, England) · 2026Article
- Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.Current topics in behavioral neurosciences · 2026Review
- Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review.BJPsych open · 2025Review
- The Psychedelic Renaissance: A Catholic Perspective.The Linacre quarterly · 2025Article
- From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.Pharmacology research & perspectives · 2025Review
- What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.Therapeutic advances in psychopharmacology · 2025Article
- Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.Therapeutic advances in psychopharmacology · 2025Review
- Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic.Frontiers in psychiatry · 2023Article
- Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists.Frontiers in psychology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What happens when an emerging programme of medical research overlaps with a surging social movement? In this article we draw on the anthropological term 'chemosociality' to describe forms of sociality born of shared chemical exposure. Psychedelic administration in the context of recent clinical trials appears to have been particularly chemosocial in nature. We argue that one consequence is that psychedelic-assisted therapy (PAT) clinical research trials tend to breach key assumptions underlying the logic of causal inference used to establish efficacy. We propose the concept of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.